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Robert Sladek15,16,17, Philippe Froguel1,18*
1 CNRS 8090-Institute of Biology, Pasteur Institute, Lille, France, 2 INSERM U695, Paris, France, 3 René Diderot-Paris 7 University, Paris, France, 4 Department of
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Abstract
Background: Recently, several Genome Wide Association (GWA) studies in populations of European descent have identified
and validated novel single nucleotide polymorphisms (SNPs), highly associated with type 2 diabetes (T2D). Our aims were to
validate these markers in other European and non-European populations, then to assess their combined effect in a large
French study comparing T2D and normal glucose tolerant (NGT) individuals.
Methodology/Principal Findings: In the same French population analyzed in our previous GWA study (3,295 T2D and 3,595
NGT), strong associations with T2D were found for CDKAL1 (ORrs7756992 = 1.30[1.19–1.42], P = 2.361029), CDKN2A/2B
(ORrs10811661 = 0.74[0.66–0.82], P = 3.561028) and more modestly for IGFBP2 (ORrs1470579 = 1.17[1.07–1.27], P = 0.0003) SNPs.
These results were replicated in both Israeli Ashkenazi (577 T2D and 552 NGT) and Austrian (504 T2D and 753 NGT)
populations (except for CDKAL1) but not in the Moroccan population (521 T2D and 423 NGT). In the overall group of French
subjects (4,232 T2D and 4,595 NGT), IGFBP2 and CXCR4 synergistically interacted with (LOC38776, SLC30A8, HHEX) and
(NGN3, CDKN2A/2B), respectively, encoding for proteins presumably regulating pancreatic endocrine cell development and
function. The T2D risk increased strongly when risk alleles, including the previously discovered T2D-associated TCF7L2
rs7903146 SNP, were combined (8.68-fold for the 14% of French individuals carrying 18 to 30 risk alleles with an allelic OR of
1.24). With an area under the ROC curve of 0.86, only 15 novel loci were necessary to discriminate French individuals
susceptible to develop T2D.
Conclusions/Significance: In addition to TCF7L2, SLC30A8 and HHEX, initially identified by the French GWA scan, CDKAL1,
IGFBP2 and CDKN2A/2B strongly associate with T2D in French individuals, and mostly in populations of Central European
descent but not in Moroccan subjects. Genes expressed in the pancreas interact together and their combined effect
dramatically increases the risk for T2D, opening avenues for the development of genetic prediction tests.
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Odds ratios were adjusted for age, gender and BMI under a multiplicative model
NGT: Normal Glucose Tolerant
T2D: Type 2 Diabetic
Allele 1: Major allele
Allele 2: Minor allele (tested)
doi:10.1371/journal.pone.0002031.t001
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The 22 SNPs located in the 14 loci that we identified in our
previous study were analyzed in other independent populations.
For each polymorphism, the best fitting genetic model was selected
from our previous whole-genome association study in French
individuals [1]. Thus, all polymorphisms were analyzed under a
multiplicative genetic model except for EXT2 (dominant model)
and KCTD12 (recessive model). For CDKAL1, CDKN2A/2B,
IGFBP2, HHEX and EXT2, we studied more than one

Scott [2]

Replication studies in 4 additional independent
populations

Genotype 1-2

We first studied whether 3 risk loci (7 SNPs) identified in
Finnish, English, and Icelandic-Danish populations conferred risk
in our original French population (3,295 T2D and 3,595 NGT).
Polymorphisms of CDKAL1, CDKN2A/2B and IGFBP2 were all
associated
with
T2D
(ORrs7756992 = 1.30
[1.19–1.42],
P = 2.361029; ORrs10811661 = 0.74 [0.66–0.82], P = 3.561028;
and ORrs1470579 = 1.17 [1.07–1.27], P = 0.0003), respectively)
(Table 1). In this population and for each SNP, the best mode
of inheritance (Pmax) was found to be multiplicative.

Genotype 1-1

Association studies in our original set of French
individuals

rs ID

Clinical characteristics of each population are reported in Table
S1. Minimum detectable effect size with a statistical power of 80%
was calculated for each SNP in all studied samples and linkage
disequilibrium was assessed between genetic variants located in the
same locus (Table S2).

Gene

Results

Whole-genome study

Table 1. Genotypic distribution by number of individuals (%) of the 7 SNPs studied in the first set of French population

T2D

OR

P

Recently, genome-wide association (GWA) studies have revealed
new single nucleotide polymorphisms (SNPs) that are strongly
associated with type 2 diabetes (T2D) [1–5]. In our French study, we
showed that the well known rs7903146 TCF7L2 polymorphism
ranked first for its effect on T2D prevalence followed by four new risk
loci: SLC30A8, HHEX, LOC387761 and EXT2 [1]. Subsequently,
GWA studies in Finnish, English, Icelandic and Danish populations
emphasized the role of CDKAL1, CDKN2A/2B and IGFBP2 on T2D
and confirmed the effect of TCF7L2, SLC30A8 and HHEX [2–5].
Additional SNPs, located in MMP26, LDLR, KCTD12, CAMTA1,
NGN3, CXCR4, LOC646279, were also among the 15 first signals in
the joint stage I and fast track stage II analyses of the French study
[1], but their current status is uncertain as they did not rank high in
the other GWA scans [2–5]. Although the other loci listed above are
likely to be true T2D markers, the actual impact of these genetic
variants in other European and non-European populations as well as
their cumulative effects and potential interactions remain to be
determined.
In the present study, we first investigated the association of
CDKAL1, CDKN2A/2B and IGFBP2 SNPs with T2D in the French
population that we analyzed in our GWA study followed by a fast
track replication [3,295 T2D and 3,595 normal glucose tolerant
(NGT)] [1]. Then, 22 SNPs in 14 loci previously associated with
T2D in GWA studies were selected and analyzed in four
additional independent populations of European [French (937
T2D and 1,000 NGT), Austrian (504 T2D and 753 NGT), Israeli
Ashkenazi (577 T2D and 552 NGT)] and Moroccan Arabic (521
T2D and 423 NGT) origin. Finally, in the overall group of French
individuals (4,232 T2D and 4,595 NGT), we assessed possible
gene-gene interactions and determined the cumulative genetic risk
of carrying risk alleles on T2D prevalence.

0.74 (0.66–0.82)

Introduction

May 2008 | Volume 3 | Issue 5 | e2031

Post GWA Study on Diabetes

polymorphism because they have all been reported as associated
with T2D in previous studies [2–5].
We first analyzed another independent French group of more
modest sample size (937 T2D and 1,000 NGT) (Table 2). Polymorphisms of predicted genes (LOC646279, ORrs1256517 = 1.44
[1.03–2.02], P = 0.03; LOC387761, ORrs7480010 = 1.32 [1.01–
1.72], P = 0.04), SLC30A8 (ORrs13266634 = 0.76 [0.59–0.97],
P = 0.03), MMP26 (ORrs2499953 = 2.45 [1.19–5.04], P = 0.01) and
CXCR4 (ORrs932206 = 0.75 [0.57–0.97], P = 0.03) were more
prevalent in T2D subjects than in NGT individuals. A trend
towards T2D association was detected for one SNP of EXT2
(ORrs3740878 = 0.50
[0.23–1.07],
P = 0.07)
and
HHEX
(ORrs1111875 = 0.79 [0.60–1.02], P = 0.07).
Then, the same SNPs were analyzed in Austrians (504 T2D and
753 NGT) (Table 3). Associations between SNPs of CDKN2A/2B
(ORrs10811661 = 0.67
[0.52–0.87],
P = 0.002),
IGFBP2
(ORrs4402960 = 1.25
[1.02–1.53],
P = 0.03),
SLC30A8
(ORrs13266634 = 0.76
[0.61–0.94],
P = 0.01)
and
NGN3
(ORrs7923837 = 0.73 [0.59–0.91], P = 0.005) loci and T2D were
identified.
In Israeli Ashkenazi subjects (577 T2D and 552 NGT),
CDKN2A/2B (ORrs564398 = 1.26 [1.03–1.53], P = 0.02), CDKAL1
(ORrs7754840 = 1.30 [1.08–1.56], P = 0.005; ORrs7756992 = 1.24
[1.03–1.49], P = 0.02), IGFBP2 (ORrs1470579 = 1.34 [1.12–1.61],
P = 0.001) and EXT2 (ORrs729287 = 0.43 [0.21–0.88], P = 0.02)
were more prevalent in the T2D group than in NGT individuals
(Table 4).
Finally, we also investigated a population of Moroccan origin
(521 T2D and 423 NGT), in which only trends for association
were found for SNPs of CDKAL1 (ORrs7754840 = 1.20 [0.99–1.46],
P = 0.06; ORrs10946398 = 1.21 [0.99–1.47], P = 0.06) and
LOC646279 (ORrs1256517 = 0.84 [0.69–1.02], P = 0.07) (Table 5).

discriminatory power of the test. A perfect test would have an
AUC of 1; a test with no discriminatory power, an AUC of 0.5.
For the 15 polymorphisms, the area under the ROC curve is 0.86
(Figure 3), corresponding to a high predictive power.

Discussion
GWA scans in Europeans [1–5] and other populations [8–11]
have recently identified and confirmed new genetic variants
associated with T2D. However, the clinical interest of these
discoveries will depend on their true contribution in other ethnic
groups as well as on their predictive value for T2D risk.
Using the same study design as our French GWA scan (joint
stage I and fast track stage II), we confirmed the strong association
of CDKAL1, CKN2A/2B and IGFBP2 SNPs with T2D previously
found by other GWA scans [2–5]. Intriguingly, these results were
not replicated in another independent French population. This
may be due to the modest sample size and/or because T2D cases
and NGT controls were not specifically selected from families with
or without history of diabetes, respectively, and/or because T2D
cases and NGT controls were not matched for BMI. Our data
show that the level of association of some SNPs with T2D depends
on factors other than just ethnicity. Similar discordant results were
also found among European cohorts from Finland [2]. However,
we replicated our previous results for SLC30A8, MMP26, CXCR4,
LOC387761 and LOC646279 SNPs, suggesting that these loci may
be truly involved in T2D risk in the French population.
In another mid-sized population from Central Europe (Austria),
associations with T2D were found only with CDKN2A/2B,
IGFBP2, SLC30A8, and NGN3 SNPs supporting the value of using
large homogeneous populations to characterize the T2D genetic
architecture in a given population. In Israeli Ashkenazi individuals, in whom one EXT2 SNP was found to be a T2D genetic
marker, CDKAL1, CDKN2A/2B and IGFBP2 SNPs were associated
with T2D, as in French subjects. Even though the TCF7L2
rs790146 SNP was previously associated with T2D in this
Moroccan group [12], no association was detected with any of
the newly studied SNPs. While this lack of association may be due
to the modest sample size or hidden biases such as population
stratification, it may also signify that other SNPs in the same genes
or located in different genes could be associated in the North
African population.
Among the 14 studied loci, only 3 (CDKN2A/2B, IGFBP2 and
SLC30A8) were found to be associated with T2D in at least 3
independent case-control groups (Table 6). Their association was
recently confirmed in other subjects of European or Japanese
origin, as for CDKAL1 and HHEX [13–17]. For the other loci,
further meta-analyses and systematic replications of GWA studies
(phase 2) are now necessary to fully evaluate their contribution to
T2D risk. In the light of discrepancies between studied
populations, GWA scans in non-European ethnic groups may
bring additional insight. Further efforts in re-sequencing [18] are
also needed to find etiologic variants causing T2D.
There is a growing interest in analyzing the combined effect of
these novel loci on T2D susceptibility. This is the first time, to
our knowledge, that potential synergistic interactions between
novel T2D loci have been shown. IGFBP2 SNPs seem to interact
with LOC38776, SLC30A8 and HHEX genetic variants. These
data are in agreement with a primary beta-cell dysfunction.
IGF2BP2 binds to the key growth and insulin signaling molecule
insulin-like growth factor 2 (IGFII) and is highly expressed in
pancreatic islets [3]. The zinc transporter ZnT8 (SLC30A8
protein) is specifically expressed in pancreatic endocrine cells and
may participate in regulating insulin exocytosis [19,20]. Simi-

Gene-gene interactions and cumulative genetic effects in
French subjects
For each studied locus, we selected the most T2D-associated
SNP, including TCF7L2 rs7903146 (N = 15) in order to assess their
cumulative effects on T2D prevalence as well as potential genegene interactions (i.e., deviation from a multiplicative model) in
the complete set of French individuals (4,232 T2D and 4,595
NGT) [6].
All pairwise combinations (N = 253) were studied for the 15
SNPs (Figure S1). We found interactions of IGFBP2 rs1470579
with LOC387761 rs7480010 (P = 0.04), SLC30A8 rs13266634
(P = 0.007) and HHEX rs7923837 (P = 0.01). Similarly, we
detected interactions of IGFBP2 rs4402960 with the same loci
(P = 0.02, P = 0.01 and P = 0.008, respectively). Furthermore,
interactions of CXCR4 rs932206 with NGN3 rs10823406
(P = 0.02) and CDKN2A/2B rs10811661 (P = 0.02) were also
found. No antagonistic effects were detected.
The percentages of individuals with increasing numbers of risk
alleles in T2D subjects and NGT individuals are shown in Figure 1.
For all SNPs, including those of EXT2 and KCTD12, we
considered their multiplicative allelic effects on T2D prevalence.
The ORs for T2D in subjects carrying increasing numbers of risk
alleles are presented in Figure 2 in comparison to the 7.5% of the
study population in the reference group that have 0 to 10 risk
alleles. After adjustment for age, body mass index (BMI) and
gender, each additional risk allele increased the odds of disease by
1.24 [1.21–1.27]. Individuals with at least 18 risk alleles (6.1% of
NGT individuals and 14.5% of T2D subjects) had an OR of 8.68
[6.37–11.83] compared to the reference group.
The predictive power of tests can be evaluated by the area
under the ROC curve (AUC) [7]. The AUC is a measure of the
PLoS ONE | www.plosone.org
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322 (47.5)

235 (34.5)

455 (66.4)

115 (28.8)

254 (59.1)

225 (51.7)

223 (54.5)

93 (24)

155 (36.6)

431 (96.4)

240 (54.9)

343 (79)

183 (41.8)

178 (41.3)

230 (52.6)

224 (53.6)

230 (53.5)

225 (51.6)

209 (47.1)

199 (45.5)

216 (48.9)

233 (51.8)

197 (48.4)

160 (36.8)

328 (74)

324 (49.7)

261 (38.8)

275 (41.2)

249 (37.3)

334 (50.8)

301 (45.6)

29 (4.2)

283 (41.9)

119 (17.5)

289 (42.4)

324 (47.4)

233 (34.7)

220 (34.3)

223 (33.4)

241 (35.3)

245 (39)

261 (39.5)

273 (41.7)

269 (38.8)

290 (42.8)

328 (48.1)

202 (29.5)

NGT

NGT

T2D

Genotype 1-2

Genotype 1-1

198 (49.5)

152 (35.3)

179 (41.1)

157 (38.4)

207 (53.4)

185 (43.6)

16 (3.6)

167 (38.2)

85 (19.6)

201 (45.9)

197 (45.7)

176 (40.3)

163 (39)

169 (39.3)

177 (40.6)

185 (41.7)

191 (43.7)

180 (40.7)

174 (38.7)

169 (41.5)

190 (43.7)

105 (23.7)

T2D

Odds ratios were adjusted for age, gender and BMI under a multiplicative model except for EXT2 (dominant) and KCTD12 (recessive)
NGT: Normal Glucose Tolerant
T2D: Type 2 Diabetic
Allele 1: Major allele
Allele 2: Minor allele (tested)
d
: Dominant genetic model
r
: Recessive genetic model
doi:10.1371/journal.pone.0002031.t003

rs11037909

rs3740878

EXT2d

EXT2

rs1113132

d

EXT2d

Sladek [1]

rs4402960
rs1470579

IGFBP2

IGFBP2

rs10946398

CDKAL1

rs7756992

CDKAL1

Steinthorsdottir [5]

Saxena [4]

rs7754840

CDKAL1

rs564398

CDKN2A/2B

Zeggini [3]

rs10811661

CDKN2A/2B

Scott [2]

rs ID

Gene

Whole-genome study

Table 3. Genotypic distribution by number of individuals (%) for the 22 SNPs studied in the Austrian population

154 (23.6)

48 (7.1)

44 (6.6)

42 (6.3)

151 (23)

99 (15)

0 (0)

62 (9.2)

9 (1.3)

94 (13.8)

106 (15.5)

39 (5.8)

40 (6.2)

46 (6.9)

48 (7)

56 (8.9)

49 (7.4)

66 (10.1)

56 (8.1)

66 (9.7)

119 (17.4)

28 (4.1)

NGT

Genotype 2-2

87 (21.8)

24 (5.6)

31 (7.1)

29 (7.1)

88 (22.7)

84 (19.8)

0 (0)

30 (6.9)

6 (1.4)

54 (12.3)

56 (13)

31 (7.1)

31 (7.4)

31 (7.2)

34 (7.8)

50 (11.3)

47 (10.8)

46 (10.4)

43 (9.6)

41 (10.1)

85 (19.5)

10 (2.3)

T2D

0.03

0.46

0.005
0.93 (0.77–1.13)

0.84
0.73 (0.59–0.91)

0.69

0.58

0.27

1.02 (0.82–1.27)

1.04 (0.84–1.29)

1.06 (0.86–1.30)

1.17 (0.88–1.56)

0.50

0.01
0.81 (0.43–1.51)

0.40
0.76 (0.61–0.94)

0.98

0.21

0.26

0.26

0.61

0.45

1.15 (0.84–1.57)

1.00 (0.82–1.22)

0.89 (0.73–1.07)

1.37 (0.79–2.37)

1.36 (0.79–2.33)

1.15 (0.68–1.94)

1.22 (0.73–2.02)

0.14

1.25 (1.02–1.53)
1.17 (0.95–1.43)

0.76

0.30

0.97

0.44

0.002

P

1.03 (0.84–1.27)

1.11 (0.91–1.37)

1.00 (0.81–1.24)

0.93 (0.77–1.12)

0.67 (0.52–0.87)

(95% CI)

OR
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6
rs2499953
rs2876711
rs6413504
rs1193179
rs7480010

MMP26

KCTD12r

LDLR

CAMTA1

LOC387761

381 (71.2)

308 (59.8)

174 (33.1)

297 (56)

145 (27.2)

295 (56.6)

481 (90.2)

278 (56.5)

403 (75.3)

232 (43.2)

219 (40.9)

347 (65.7)

339 (64.8)

343 (64.2)

347 (65)

191 (38.5)

160 (35.3)

168 (39.2)

229 (48.2)

199 (43.4)

271 (54.7)

371 (72.3)

379 (69.8)

304 (56.7)

205 (38.2)

310 (59.4)

134 (24.9)

272 (50.9)

505 (92.7)

301 (58.1)

393 (72.4)

241 (44.7)

237 (44.1)

379 (70.8)

159 (30.4)

369 (68.7)

378 (70)

155 (30.3)

148 (30.3)

150 (35.1)

208 (40.5)

179 (34.9)

251 (48.3)

395 (75)

143 (26.7)

179 (34.8)

276 (52.5)

198 (37.4)

257 (48.2)

189 (36.3)

52 (9.8)

183 (37.2)

122 (22.8)

247 (46)

256 (47.9)

155 (29.4)

25 (4.8)

165 (30.9)

162 (30.3)

232 (46.8)

208 (45.9)

200 (46.6)

201 (42.3)

205 (44.8)

190 (38.4)

130 (25.3)

NGT

NGT

T2D

Genotype 1-2

Genotype 1-1

150 (27.6)

199 (37.1)

243 (45.2)

179 (34.3)

278 (51.7)

229 (42.9)

38 (7)

187 (36.1)

135 (24.9)

233 (43.2)

226 (42.1)

144 (26.9)

361 (69)

151 (28.1)

147 (27.2)

252 (49.2)

256 (52.5)

205 (48)

236 (46)

247 (48.1)

220 (42.3)

122 (23.1)

T2D

Odds ratios were adjusted for age, gender and BMI under a multiplicative model except for EXT2 (dominant) and KCTD12 (recessive)
NGT: Normal Glucose Tolerant
T2D: Type 2 Diabetic
Allele 1: Major allele
Allele 2: Minor allele (tested)
d
: Dominant genetic model
r
: Recessive genetic model
doi:10.1371/journal.pone.0002031.t004

rs932206

rs13266634

SLC30A8

rs10823406

rs1256517

LOC646279

CXCR4

rs7923837

HHEX

NGN3

rs729287

rs11037909

EXT2d

rs1111875

rs3740878

EXT2d

HHEX

rs1113132

EXT2d

rs1470579

IGFBP2

EXT2d

Steinthorsdottir [5]

rs4402960

IGFBP2

rs7756992
rs10946398

CDKAL1

CDKAL1

Sladek [1]

Saxena [4]

rs7754840

CDKAL1

rs564398

CDKN2A/2B

Zeggini [3]

rs10811661

CDKN2A/2B

Scott [2]

rs ID

Gene

Whole-genome study

11 (2.1)

28 (5.4)

76 (14.4)

35 (6.6)

131 (24.6)

37 (7.1)

0 (0)

31 (6.3)

10 (1.9)

58 (10.8)

60 (11.2)

26 (4.9)

144 (27.5)

26 (4.9)

25 (4.7)

73 (14.7)

85 (18.8)

61 (14.2)

45 (9.5)

54 (11.8)

34 (6.9)

12 (2.3)

NGT

Genotype 2-2

Table 4. Genotypic distribution by number of individuals (%) of the 22 SNPs studied in the Israeli Ashkenazi population

14 (2.6)

33 (6.2)

89 (16.6)

33 (6.3)

126 (23.4)

33 (6.2)

2 (0.4)

30 (5.8)

15 (2.8)

65 (12.1)

74 (13.8)

12 (2.2)

18 (3.4)

17 (3.2)

15 (2.8)

105 (20.5)

84 (17.2)

72 (16.9)

69 (13.5)

87 (17)

49 (9.4)

10 (1.9)

T2D

1.07 (0.84–1.36)

1.10 (0.89–1.35)

0.96 (0.80–1.15)

0.92 (0.75–1.13)

1.01 (0.84–1.20)

1.24 (0.97–1.60)

0.77 (0.50–1.18)

0.97 (0.80–1.18)

1.18 (0.93–1.51)

0.96 (0.80–1.16)

0.97 (0.81–1.16)

0.43 (0.21–0.88)

0.72 (0.38–1.35)

0.65 (0.34–1.24)

0.57 (0.29–1.12)

1.34 (1.12–1.61)

1.09 (0.90–1.31)

0.58

0.37

0.64

0.42

0.95

0.09

0.22

0.76

0.18

0.69

0.72

0.02

0.30

0.19

0.10

0.001

0.38

0.14

0.02
1.15 (0.95–1.39)

1.24 (1.03–1.49)

0.02
0.005

1.30 (1.08–1.56)

0.34
1.26 (1.03–1.53)

P

0.89 (0.69–1.14)

(95% CI)
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rs729287
rs1111875
rs7923837
rs1256517
rs13266634
rs2499953
rs2876711
rs6413504
rs1193179
rs7480010
rs10823406
rs932206

EXT2d

HHEX

HHEX

LOC646279

SLC30A8

MMP26

KCTD12r

LDLR

CAMTA1

LOC387761

NGN3

CXCR4

305 (72.5)

304 (72.9)

151 (36.4)

134 (31.9)

139 (33.4)

192 (48.9)

372 (89.9)

292 (69.4)

182 (43.3)

227 (53.8)

177 (42.2)

319 (75.8)

308 (73.7)

306 (72.7)

317 (75.7)

133 (31.7)

149 (36.3)

204 (48.8)

204 (48.9)

204 (48.8)

243 (58)

288 (69.4)

346 (67.2)

351 (69.2)

173 (33.3)

150 (29.4)

180 (34.8)

271 (52.1)

451 (88.6)

360 (69.6)

248 (48.5)

300 (57.9)

236 (46)

397 (76.3)

386 (74.8)

388 (75)

395 (76.1)

145 (28.1)

169 (32.6)

231 (44.6)

238 (45.8)

232 (44.8)

323 (62.6)

368 (71)

102 (24.2)

100 (24)

201 (48.4)

213 (50.7)

208 (50)

164 (41.7)

40 (9.7)

118 (28)

188 (44.8)

158 (37.4)

187 (44.6)

97 (23)

104 (24.9)

110 (26.1)

97 (23.1)

199 (47.4)

196 (47.7)

176 (42.1)

172 (41.2)

176 (42.1)

148 (35.3)

116 (27.9)

NGT

NGT

T2D

Genotype 1-2

Genotype 1-1

153 (29.7)

142 (28)

249 (48)

261 (51.1)

242 (46.7)

204 (39.2)

57 (11.2)

145 (28.1)

216 (42.3)

183 (35.3)

227 (44.2)

114 (21.9)

120 (23.3)

119 (23)

114 (22)

247 (47.8)

253 (48.7)

220 (42.5)

225 (43.3)

219 (42.3)

170 (33)

127 (24.5)

T2D

Odds ratios were adjusted for age, gender and BMI under a multiplicative model except for EXT2 (dominant) and KCTD12 (recessive)
NGT: Normal Glucose Tolerant
T2D: Type 2 Diabetic
Allele 1: Major allele
Allele 2: Minor allele (tested)
d
: Dominant genetic model
r
: Recessive genetic model
doi:10.1371/journal.pone.0002031.t005
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Saxena [4]
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rs ID
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Table 5. Genotypic distribution by number of individuals (%) of the 22 SNPs studied in the Morrocan population

14 (3.3)

13 (3.1)

63 (15.2)

73 (17.4)

69 (16.6)

37 (9.4)

2 (0.5)

11 (2.6)

50 (11.9)

37 (8.8)

55 (13.1)

5 (1.2)

6 (1.4)

5 (1.2)

5 (1.2)

88 (20.9)

66 (16.1)

38 (9.1)

41 (9.8)

38 (9.1)

28 (6.7)

11 (2.6)

NGT

Genotype 2-2

16 (3.1)

14 (2.8)

97 (18.7)

100 (19.6)

96 (18.5)

45 (8.7)

1 (0.2)

12 (2.3)

47 (9.2)

35 (6.8)

50 (9.8)

9 (1.7)

10 (1.9)

10 (1.9)

10 (1.9)

125 (24.2)

97 (18.7)

67 (12.9)

57 (11)

67 (12.9)

23 (4.5)

23 (4.4)

T2D

1.18 (0.92–1.51)

1.16 (0.91–1.49)

1.11 (0.92–1.34)

1.09 (0.90–1.32)

0.98 (0.82–1.18)

0.89 (0.68–1.16)

1.06 (0.71–1.59)

0.99 (0.77–1.27)

0.84 (0.69–1.02)

0.88 (0.72–1.08)

0.87 (0.71–1.05)

1.44 (0.47–4.40)

1.30 (0.46–3.64)

1.53 (0.51–4.58)

1.55 (0.52–4.64)

1.12 (0.94–1.34)

1.11 (0.92–1.33)

1.21 (0.99–1.47)

1.12 (0.92–1.37)

1.20 (0.99–1.46)

0.83 (0.66–1.03)

0.99 (0.78–1.26)

(95% CI)

OR

0.19

0.24

0.26

0.36

0.85

0.37

0.78

0.95

0.07

0.21

0.15

0.52

0.84

0.45

0.43

0.22

0.28

0.06

0.25

0.06

0.09

0.97

P
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Figure 1. Percentage distribution of NGT and T2D individuals
by number of risk alleles.
doi:10.1371/journal.pone.0002031.g001

larly, the CXCR4 risk variant was found to interact with NGN3
and CDKN2A/2B SNPs. It was reported that CXCR4-positive
pancreatic cells express markers of pancreatic endocrine
progenitors such as NGN3 [21]. CDKN2A could be a possible
biological candidate for T2D [22] as its over-expression in
rodents causes a decrease in islet proliferation [23]. The
emerging picture of these possible interactions emphasizes the
ability of multiple SNPs to potentiate their deleterious effects in
both beta-cell development and function.
The evaluation of the T2D risk in individuals carrying
increasing numbers of risk variants is critical for a potential
clinical use of a genetic test in the general population. It was
previously shown that UK individuals with TCF7L2, PPARG and
KCNJ11 risk alleles had an OR of 5.71-fold (95% CI, 1.15 to 28.3)
compared to those with no risk alleles, for an AUC of 0.58 [6]. It
has been suggested that 20–25 risk variants with allele frequencies
greater than 0.1 and ORs of 1.5 are required for an AUC of about
0.8 [24]. In our study, with only 15 SNPs, we reached a good
discriminating power to identify individuals with high susceptibility for T2D. After adjustments for age, BMI and gender, subjects
with at least 18 risk alleles (14.5% of French T2D subjects) had
approximately 9-fold higher risk of developing T2D compared to

Figure 3. ROC for the information provided by the 15 T2Dassociated genetic variants. We used a logistic regression model
adjusted for age, gender and BMI including a covariate for the number
of risk alleles. The area under the ROC curve was 0.86. Academic point
system: 0.90–1 = excellent; 0.80–0.90 = good; 0.70–0.80 = fair; 0.60–
0.70 = poor; 0.50–0.60 = fail.
doi:10.1371/journal.pone.0002031.g003

the reference group, for an AUC of 0.86. If confirmed, this
increase in T2D risk due to genetic factors is even higher than that
due to severe obesity (OR = 7.37) [25], the most established T2D
risk factor.
After many years of limited success, the genetic architecture of
T2D (common SNPs) is finally being uncovered by GWA studies.
Even though the absence or presence of association in a given
population is dependent on many factors (e.g., number of
individuals, ethnicity, SNP prevalence, BMI, familial history of
T2D and others), replication studies certainly help in validating
SNPs truly associated with T2D and in excluding false positives.
Our data support the concept that T2D loci may interact
together. Consequently, while single polygenic susceptibility
variants may be of limited use in disease prediction, the combined
information from a number of these variants should allow the
identification of groups of subjects at high and low risk of
developing a complex disease [26]. Hence, our study opens up the
way to new applications in public health, based on early genetic
testing for better prevention and care.

Materials and Methods
Study design
We first investigated the association with T2D of CDKAL1,
CDKN2A/2B and IGFBP2 SNPs in the same French population
analyzed in our previous GWA study (3,295 T2D and 3,595
NGT). These 3 loci were selected for their high degree of
association with T2D in GWA studies and their ability to be
replicated in different populations of European origin [2–5]. In
addition to these 3 loci, the role of 11 additional loci for which we
found the 15 highest SNP association signals (except for TCF7L2)
in the joint stage I and fast track stage II of the French GWA scan
[1] (SLC30A8, HHEX, EXT2, LOC646279, MMP26, KCTD12,
LDLR, CAMTA1, LOC38776, NGN3 and CXCR4) was evaluated in
4 additional independent groups (2,539 T2D and 2,728 NGT) of

Figure 2. Odds ratios for French individuals carrying increasing
numbers of risk alleles. Fifteen T2D genetic variants identified by
GWA studies were analyzed in 4,232 T2D and 4,595 NGT French subjects
for their cumulative effects on T2D prevalence. Allelic ORs and 95%-CIs
were calculated using logistic regression model adjusted for age,
gender and BMI. They are presented for each group, defined by their
number of T2D risk alleles. Each additional allele increases in average
the risk to develop T2D by 24 % (P = 8610271).
doi:10.1371/journal.pone.0002031.g002
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Table 6. Summary of replication results in the 5 case-control groups

Whole-genome study

Gene

French (First set)

French (Second set)

Austrian

Israeli Ashkenazi

Morrocan

Total

Scott [2]

CDKN2A/2B

+

-

+

+

-

+++

Zeggini [3]

CDKAL1

+

-

-

+

-

++

Saxena [4]

IGFBP2

+

-

+

+

-

+++

Steinthorsdottir [5]
Sladek [1]

EXT2

(+)

-

-

+

-

++

HHEX

(+)

-

-

-

-

+

LOC646279

(+)

+

-

-

-

++

SLC30A8

(+)

+

+

-

-

+++

MMP26

(+)

+

-

-

-

++

KCTD12

(+)

-

-

-

-

+

LDLR

(+)

-

-

-

-

+

CAMTA1

(+)

-

-

-

-

+

LOC387761

(+)

+

-

-

-

++

NGN3

(+)

-

+

-

-

++

CXCR4

(+)

+

-

-

-

++

+: At least one SNP detected associated with T2D
-: No SNP detected associated with T2D
( ) : Previously known data
doi:10.1371/journal.pone.0002031.t006

European (French, Austrian and Israeli Ashkenazi) and nonEuropean (Moroccan) origin. Finally, in all French subjects, we
assessed the cumulative genetic risk of carrying the studied risk
alleles on T2D prevalence and their possible interactions,
including the previously discovered T2D-associated TCF7L2
rs7903146 SNP.

throughout France between 2001 and 2004) designed to assess the
genetic determinants of diabetic nephropathy in type 2 diabetes.
T2D was diagnosed on clinically determined absence of type 1 or
secondary diabetes, in individuals of more than 40 years of age at
onset and without insulin treatment within 2 years after disease
onset. Each patient record was carefully checked by an
adjudication committee to ascertain T2D status and diabetic
complications. 21 ml of blood drawn on EDTA were used for
DNA extraction using standard procedures (ethanol precipitation)
and samples were stored at –80uc until use. The number of
recruited people was 11 in December 2001 (first month of the
study), 491 subjects in 2002, 514 in 2003, 593 in 2004, 897 in 2005
and 229 thereafter.
The Austrian subjects were of Bavarian and Austrian German
descent and came from the greater region of Salzburg, Austria.
They were recruited between April 1999 and December 2002.
Unrelated patients with type 2 diabetes were recruited from
diabetes outpatient clinics of the Landeskliniken Salzburg and the
Hospital Hallein (near Salzburg). The diagnosis of T2D was based
on use of hypoglycemic agents or plasma glucose values
.126 mg/dl (in absence of treatment). The patients were seen
repeatedly and managed by the outpatient clinics. Participants in
the Salzburg Atherosclerosis Prevention Program in Subjects at
High Individual Risk (SAPHIR) [12,30–32] who were not using
hypoglycemic medications and had fasting plasma glucose levels
,110 mg/dL served as NGTcontrols. SAPHIR was a populationbased prospective study that investigated the involvement of
factors contributing to the control of plasma lipid transport and
carbohydrate metabolism in the progression of atherosclerotic
vascular disease. Unrelated men and women subjects with an age
range between 39 and 67 years who live in the greater Salzburg
region and responded to invitations by their family or workplace
physician or to announcement in the local press were included in
the study. Average rates of recruitment were 10 controls/week and
3 T2D subjects/week. For all samples, whole blood was collected
after an overnight fast in tubes containing 1.6 mg/ml EDTA.

Study populations
The main clinical characteristics of each studied population
were presented in Table S1. The first French group of T2D
subjects and NGT controls was previously described [1].The
second set of French samples includes NGT individuals from the
‘‘Supplémentation en Vitamines et Minéraux Antioxydants’’
(SU.VI.MAX) cohort [27] and T2D subjects from the ‘‘DIABete
de type 2, NEPHROpathie et GENEtique’’ (DIAB2.NEPHRO.GENE) study [28].
The SU.VI.MAX study was a French population-based
prevention trial designed to evaluate the impact of a daily
antioxidant supplementation at nutritional doses on the incidence
of ischemic heart disease and cancer. All participants were
recruited from throughout France between October 1994 and
June 1995. [29]. The NGT controls were selected when having no
hypoglycemic treatment and a fasting glucose ,6.1 mmol/l. At
baseline, a 35-mL venous blood sample was obtained from
participants who had been fasting for 12 hr at the time of the visit.
The samples were collected in vacutainer tubes that do not
interfere with the concentration of trace elements (Becton
Dickinson). After collection, blood was kept at +4uC in the dark
until centrifugation. Centrifugation was realized at standard time,
gravity, and temperature. The time elapsing between collection
and aliquoting was recorded for all samples; it was less than 1 hr.
Aliquots were stored at 220uC in the mobile units and field
centers for, at the most, 7 days prior to shipment in dry ice to the
reference laboratories and coordinating center.
The DIAB2.NEPHRO.GENE study was a French multi-center
case-control study (15 diabetes and 5 nephrology centers from
PLoS ONE | www.plosone.org
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Plasma was separated ,30 min after collection and used
immediately for analysis. Aliquots were stored at –70uC. Aliquots
of blood collected in EDTA were stored at –70uC. Genomic DNA
was extracted from whole blood and stored at –20uC prior to
analysis.
All Israeli NGT/T2D subjects lived and were ascertained in
Israel with the help of 15 major diabetes treatment centers
throughout the country. They were of Ashkenazi Jewish origin,
defined as having all 4 grandparents born in Northern or
Eastern Europe. Subjects with known or suspected Sephardic
Jewish or non-Jewish ancestry were excluded. Thus, only Jewish
subjects were recruited and Jewish patients from the Mediterranean basin, the Persian Gulf region (Iraq, Iran), Yemen,
Ethiopia and other areas that were populated with Jews before
the major Roman exile of 70 C.E. were not included. The T2D
patients were ascertained between 2002 and 2004 in 15 diabetes
clinics throughout Israel by the ‘‘Israel Diabetes Research
Group’’ and were defined according to WHO criteria (fasting
glucose .140mg/dl on two or more occasions, or random
glucose .200 mg/dl on two or more occasions). To avoid lateonset type 1 diabetics, patients who became insulin-dependent
within 2 years of diagnosis were excluded. The average age at
diagnosis was 47 years old. The NGT controls were defined as
Ashkenazi (Northern and Eastern European ancestry) with no
history of glucose intolerance or T2D and were purchased from
the National Laboratory for the Genetics of Israeli Populations
(http://www.tau.ac.il/medicine/NLGIP/nlgip.htm). They denied ever having been diagnosed with elevated blood glucose
level, T2D or glucose intolerance. Whole blood samples were
obtained in vacuum tubes containing EDTA. The samples
were stored at 4uC and transferred to the Endocrine Laboratory
at the Hadassah Hospital, Jerusalem Israel within 72h of
collection. DNA was extracted using the Puregene Genomic
DNA extraction kit purchased from Gentra Systems, Minneapolis, MN, U.S.A. according to the manufacturer’s recommendations. Concentrated DNA was stored at 280uC, diluted
stocks were stored at 220uC and working solutions were stored
at 4uC.
Moroccan subjects were recruited, between February and July
2006, by the Faculty of Medicine (Fes) within the framework of
the Genetic project Diabetes Morocco (GenDiabM: ,180
subjects by month) and were subjected to a standardized clinical
examination at the Hassan II Hospital and in regional health
centers. The NGT and T2D subjects were from two Moroccan
regions: Fes-Tounate (central-North region) and Rabat-Sale
(western region). Patients with T2D were recruited from a
registry of associations for T2D and health centers when they
had a family history of T2D in first degree relatives. The
diagnosis of T2D was made according to the 1997 American
Diabetes Association criteria or on being treated with medications for diabetes. The NGT controls were recruited from an
unselected population undergoing a routine health check-up at
the same health centers. All control individuals $40 years of age,
not previously diagnosed for T2D, with no history of T2D in
first-degree relatives, and with fasting plasma glucose
,6.1 mmol/l. Blood and serum samples (9 ml) were collected
from all individuals and were immediately stored in frozen
conditions (serum at 220uC and blood at 280uC) until use.
Genomic DNA was then extracted from whole blood and stored
at 220uC.
In all populations, the studied individuals were unrelated to
each other (with no first-degree relatives). This genetic study was
approved by local Ethical Committees and written informed
consent was obtained from all participants.
PLoS ONE | www.plosone.org

SNP genotyping
All the polymorphisms were genotyped using an allelic
discrimination assay-by-design TaqMan method on ABI 7900
(Applied Biosystems). All genotypic distributions were in HardyWeinberg equilibrium. The genotyping success rate was higher
than 98% for each SNP. For each SNP, the genotyping error rate
was reported in Table S2 and assessed by randomly re-genotyping
384 participants in each population.

Statistical analysis
Odds ratios were assessed by logistic regression models
adjusted for age, BMI and gender. In Tables 2–5 and in Table
S2, we tested the effect of the minor allele. In these tables, the
risk allele is the minor allele if the OR is .1 and is the major
allele if the OR is ,1. The replication of an association with
T2D was considered positive on the condition that the risk allele
was not different from what was found in previous GWA studies.
For each population, a simple Bonferroni correction (multiplication by the number of SNPs) was applied to the P values for
multiple comparisons. After correction, no association remained
significant, except for those found in our original French
population. However, in the context of replication, it remains
unlikely to detect an effect due to statistical fluctuation only. We
explored the effect of multiple SNPs using a logistic regression
model including a variable for the number of risk alleles in order
to quantify the risk per supplementary allele for all the variants
included in the model. OR corresponding to a given number of
risk alleles compared to the reference group was also calculated.
We evaluated the ability of this model to discriminate between
NGT and T2D individuals with a Receiver Operating
Characteristic (ROC) curve [33] using a logistic regression
model adjusted for age, gender and BMI including a covariate
for the number of risk alleles of the 15 studied variants. The Area
Under the ROC Curve (AUC) was calculated as a measure of
the discriminative power of the test. Gene-gene interactions (i.e.,
deviation from a multiplicative model) were tested by comparing
a logistic regression model including only the main effects to
another model including the main effects and an interaction
term with a likelihood ratio test. We further explored the way
two variants interact with interaction plots. We used Quanto
(http://hydra.usc.edu/GxE/) for power calculations. Pairwise
linkage disequilibrium between genetic markers was assessed
using the R ‘‘genetics’’ package (version 1.3.2). All P values are
two-sided. SPSS (version 14.0.2) and R statistics (version 2.5.1)
software were used for general statistical analysis.

Supporting Information
Figure S1 Significant gene-gene interactions between genetic
variants and T2D. 1: Homozygous for the protective allele; 2:
Heterozygous; 3: Homozygous for the risk allele. The minimum
number of samples by genotype intersection and by status is
presented thereafter. A: 48, B: 27, C: 43, D: 37, E: 41, F: 31, G:
42, H: 16.
Found at: doi:10.1371/journal.pone.0002031.s001 (0.24 MB TIF)
Table S1 Clinical characteristics of the studied populations.
Found at: doi:10.1371/journal.pone.0002031.s002 (0.04 MB
DOC)
Table S2 Linkage disequilibrium and minimum detectable effect

size with a statistical power of 80% for the 22 SNPs in the 5 casecontrol groups.
Found at: doi:10.1371/journal.pone.0002031.s003 (0.12 MB
DOC)
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